Skip to main content
Healthcare

STAT+: RevMed’s pancreatic cancer drug nears European approval

STAT+: RevMed’s pancreatic cancer drug nears European approval

Feed excerpt — reported by STAT News

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.